Global Cystic-Fibrosis Therapeutics Market By Drug Class (CFTR modulators, Mucolytic, Pancreatic enzyme supplements and Bronchodilators), By Route of Administration (Oral drugs and Inhaled drugs), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

Cystic-Fibrosis Therapeutics Market Overview

In 2021, The Global Cystic-Fibrosis Therapeutics Market was valued at USD 6,836.4 Million. It is expected to grow at a CAGR of 13.94% from 2023-2032 due to its rising prevalence and treatment rates.

The Market will be driven by a number of key factors, including a rise in R&D funding from both public and private organizations, the rise in initiatives by non-profit organizations, and promising reimbursement policies. The Cystic Fibrosis Foundation published data showing that the prevalence of these hereditary conditions is increasing. The number of patients with Cystic Fibrosis in the United States was 58,983 Million in 2020, compared to 47,366 in 2019. The demand for effective and efficient CF therapies is increasing year on year due to an increase in patients. Cystic Fibrosis Transmembrane Conductance Regulator, (CFTR), bronchodilator drugs, and mucolytic drugs are some of the approved drug classes.

Global Cystic-Fibrosis Therapeutics Scope:

Drug Class Analysis:

Based on drug class, the market can be divided into pancreatic enzyme supplements, mucolytics, and bronchodilators. The main consideration for CF treatment is to maintain lung function, control respiratory infection, clear the airways of saliva, and manage the nutritive therapy. Kalydeco, the initial CFTR modulator, was introduced in the U.S. in 2019. It was still the only CFTR moderator drug available in 2020.
The launch of Orkambi, a new drug that targets CFTR modulators, was responsible for the highest share of revenue in 2021, at 47.3%. This drug corrects the purpose of the faulty protein produced by the CF gene. These drug class straight treats the original cause. The main factor contributing to its share is its product introduced in 2015. CFTR modulators are also expected to see profitable growth at a rate of 24.2% during the prediction period.

Route of Administration Analysis

The Market can be divided into two types of routes depending on how it is administered. With a nearly 63.7% share, the oral route was the most popular. This is due to its ease of use and convenience. The key factor driving demand for oral drugs in emerging countries is the growing awareness of their benefits, including CFTR modulators as well as pancreatic enzyme supplementation. Orally administered therapeutics include CFTR modulators like KALYDECO or ORKAMBI, as well as pancreatic enzyme supplements such as PERTZYE and Creon/Zenpep. The oral drug Market will be driven by the high commercial obtainability and large demand for these drugs to delicacy CF. According to the U.S. Patient Registry 2020, hypertonic Saline was prescribed to 11.5% of children aged 0-3 years and 42.9% of children aged 3-3 years. One of the main reasons for the growing request for oral drug formulation is the increasing incidence of CF in newborn babies.

The Market is expected to grow due to an increase in clinical trials that expand the patient base. The segment is also expected to grow at a profit of 20.1% during the forecast era. This segment will also see a growing number of public and private players invest in it.

Маrkеt Ѕеgmеntѕ:

Drug Class

• CFTR modulators
• Mucolytics
• Pancreatic enzyme supplements
• Bronchodilators

Route of Administration

• Oral drugs
• Inhaled drugs

Market Dynamics

Market growth will be driven by a growing number of drug compositions being developed by the major players. This Market is driven by a growing number of clinical trials that aim to increase the patient base and expand the drug portfolio. Market growth is expected to be driven by increasing R&D activities. The pipelined drugs include (VX-445 + Tezacaftor + Ivacaftor); QR-010; AZD-55634; and, POL-6014.
One of the key factors behind the surge in demand is the presence of many non-profit organizations like Cystic Fibrosis Worldwide and Cystic Fibrosis Foundation, Cystic Fibrosis Canada, and South African Cystic Fibrosis Trust. These organizations invest huge sums of money to help develop and research new therapies for CF.

Regional Analysis

The Market can be divided by region into Europe, North America and the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America was the most lucrative region with USD 5,396.4 million. North America is the most affected region for CF, with most people living with it being Caucasian. Cystic Fibrosis Canada and CF Foundation are two of the reasons why CF is so prevalent.
The Asia Pacific will be the fastest-growing section, with an 18.8% growth rate. Despite the fact that CF is less common in the Asia Pacific due to the lack of Nation-specific registries and underdiagnoses, this Market will see a rise in consciousness about CF disorders and treatment options over the forecast period. The Market will be boosted by the region’s economic development and improved healthcare facilities over the prediction period.

The Market will be boosted by the awareness of healthcare professionals and patients about the new therapeutic options available in the market. Currently, there are not many CF-specific drugs available. However, product launches and approvals in this Market are expected to drive growth.

Кеу Regions and Countries covered іn thе rероrt:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Market Share & Key Players Analysis:

Cystic Fibrosis is treated by a variety of products, and the key players are involved in their development. Strategic measures include investing in R&D to outperform the competition. Vertex Pharmaceuticals Inc., AbbVie, Inc., Gilead, Novartis AG, F. Hoffmann-La Roche Ltd, AIT (Advanced Inhalation Therapies); Merck & Co. Alaxia Pharmaceutical Industries Ltd., Inc., Alcresta Therapeutics, Inc., Allergan, and AstraZeneca are the key players in this Market

Market Key Players:

• Hoffmann-La Roche Ltd.
• Gilead
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Vertex Pharmaceuticals Inc.
• Alcresta Therapeutics
• Merck & Co. Inc.
• AIT (Advanced Inhalation Therapies)
• Other Key Players

For the Cystic-Fibrosis Therapeutics Market research study, the following years have been considered to estimate the market size: